Online registration is now closed, there will be a limited number of onsite registrations on Monday

The convergence between digital health and the life sciences is creating new opportunities to transform patient care as well as drug discovery and development. From wearables to machine learning, digital technologies are easing data collection from patients, increasing medical adherence, reshaping clinical trials, and offering new insights into real-world applications of therapies. Embedding digital health tools into the life sciences will also allow new therapies to better work within the growing value-based healthcare system that relies on data and measurable outcomes.

Join MassBio for our inaugural Digital Health Impact 2019 event at the InterContinental Boston at 510 Atlantic Ave, Boston, MA 02210, part of Biotech Week Boston, as we examine the current state of digital health as it relates to the life sciences, the challenges facing its growth, and opportunities for collaboration. Through keynotes, panel discussions, and case studies, we’ll explore new strategies for life sciences and digital health innovators to converge and ultimately deliver better outcomes for patients. Contact Laura Rudberg for sponsorship opportunities. View our sponsorship prospectus here

CMO & Head of Clinical Development, Pear Therapeutics
Dr. Maricich leads the Clinical/Regulatory team at Pear Therapeutics as the Chief Medical Officer and Head of Clinical Development. He leads and manages the clinical development programs from Discovery/TPP to Therapeutic, Translational, Clinical Development, through Regulatory submission and prosecution. In addition to overseeing subsequent pipeline programs, including reSET-O (1st drug/software combination), Dr. Maricich leads Medical Affairs. Dr. Maricich is a licensed, board-certified physician, investor, clinical developer and strategist. He works to improve patient health and our healthcare system by providing care, investing in, advising, and providing leadership at innovative firms. He has worked with and lead successful teams and programs at Healthcare & Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by Cavion), Cavion, AWS, and Pear Therapeutics (1st FDA-cleared, clinically validated digital therapeutic to treat disease) and maintains clinical practice. He founded a digital health firm while a 3rd year med student that used AI and NLP to structure clinical data. Dr. Maricich earned his M.D. degree at the University of Washington School of Medicine, M.B.A from Harvard University, and his undergraduate at the University of Notre Dame. He completed internal medicine training at the University of Virginia Health System.

Brought to you by